drugset / Trial / NCT00438581
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Phase 2
Unknown
40 enrolled
McGill University
McGill University Health Centre/Research Institute of the McGill University Health Centre · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This aim of this study to evaluate the safety and efficacy of combining a single course of Yttrium 90 Ibritumomab Tiuxetan, a radiolabeled monoclonal antibody ( Zevalin ), with high-dose BEAM chemotherapy and autologous peripheral stem cell transplantation in patients with relapsed, refractory, or transformed Non-Hodgkin's lymphoma.
Timeline
- Start
- 2007-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Yttrium 90 Ibritumomab Tiuxetan | Monoclonal antibody | — | — |